Your browser doesn't support javascript.
Safety of a third SARS-CoV-2 mRNA vaccine dose in people with multiple sclerosis
Multiple Sclerosis Journal ; 28(3 Supplement):480-481, 2022.
Article in English | EMBASE | ID: covidwho-2138897
ABSTRACT
Background and goals The goal of this study was to assess the rate of self-reported side effects, need for medical assistance and hospitalizations after a third COVID-19 vaccination in people with multiple sclerosis (pwMS) with or without disease-modifying treatments. We also wanted to investigate if SARS-CoV2 antibody levels correlate with side effects. Method(s) Participants enrolled in the vaccination trial Nevrovax were invited to complete a questionnaire on side effects after the third dose of SARS-CoV-2 vaccination. SARS-CoV2 antibodies were measured in BAU/mL after 3 weeks or longer after vaccination. The results were linked to data from the Norwegian Immunization Registry. Statistical analyses were performed using SPSS Stastistics version 26. Group comparisons were analyzed using independent samples t-tests and chi-square tests with a significance level of 0.05. Result(s) In total 606 pwMS (77.4% female, mean age 48.3 years) were included in this study. At the time of immunization, 61.7% of all pwMS were treated with anti-CD20 monoclonal antibodies and 19%with sphingosine 1-phosphate receptor modulators. Mean time to follow up from third dose to answering the questionnaire was 29.9 days.586 patients received an mRNAvaccine (257 BNT162b2 and 344 mRNA1273 as dose 3) while 20 received a viral vector vaccine-AZD1222 (One as dose 3). Data on vaccine type of dose 3 was missing in 4 patients. Side effects were reported by 66.2% of all pwMS. Mean age of patients with and without side effects were 47.0and 50.7 years, respectively (p < 0.01). We found a higher rate of side effects among women (68.8%) than men (59.1%) (p=0.047), and a higher rate among those using anti-CD20 therapy (73.3%) (p<0.05). Blood samples of SARS-CoV2 antibodies were obtained in 547 patients. There were no significant difference in antibody levels in patients with side effects (mean 1185 BAU/ mL) and patients without side effects (mean 1174 BAU/mL), p= 0.66. 16 pwMS (2.6%) sought medical help after vaccination. No pwMS needed hospitalization. Conclusion(s) Our results demonstrate that a third dose of SARSCov2 vaccines are safe in pwMS using different DMTs. Rate and severity of side effects vary with both treatment and demographic factors. SARS-CoV2 IgG levels did not correlate with side effects. There were no hospitalizations after vaccination with a 3rd dose.
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Multiple Sclerosis Journal Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Multiple Sclerosis Journal Year: 2022 Document Type: Article